Therefore, we conducted a retrospective study to further validate peripheral blood markers in predicting outcome and prognosis in patients with advanced NSCLC treated with PD-1 inhibitors-based combination therapy. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.